• 1
    Schmall HJ, Buchele T, Grothey A, Dempke W. . Where do we stand with 5-fluorouracil? Semin Oncol 1999; 26: 589605.
  • 2
    Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 1989; 16: 215237.
  • 3
    Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clin Pharmacokin 1999; 36: 391398.
  • 4
    Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 22032206.
  • 5
    Schaaf LJ, Dobbs BR, Edwards IR, Perrier DG. Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur J Clin Pharmacol 1987; 32: 411418.
  • 6
    Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197201.
  • 7
    Goldberg J, Kerr DJ, Watson DG, et al. The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. Br J Cancer 1990; 61: 913915.
  • 8
    Larsson PA, Carlsson G, Gustavsson B, Graf W, Glimelius B. Different intravenous administration techniques for 5-fluorouracil, pharmacokinetic and pharmacodynamic effects. Acta Oncol 1996; 35: 207212.
  • 9
    Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric perspective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16: 14701478.
  • 10
    Gusella M, Toso S, Menon D, et al. Can AUC predict toxicity following 5-fluorouracil i.v. bolus administration? Pharm Res 2001; 43(Suppl A): 161(Abstract).
  • 11
    Dollery C. Therapeutic Drugs, 2nd edn. London: Churchill Livingstone 1999; p. F103.
  • 12
    Domin BA, Mahony WB, Zimmerman TP. Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem Pharmacol 1993; 46: 503510.
  • 13
    Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE. Nonlinear pharmacokinetic models for 5-fluorouracil in man. intravenous and intraperitoneal routes. Clin Pharmacol Ther 1980; 28: 235246.
  • 14
    Zarowitz BJ. Bioelectrical impedance analysis measurements for drug pharmacokinetics. Am J Clin Nutr 1996; 64(Suppl): 519S23S.
  • 15
    Kotler DP, Burastero S, Wang J, Pierson RN. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996; 64(Suppl): 489S97S.
  • 16
    O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246250.
  • 17
    Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area. A height-weight formula validated in infants, children, and adults. J Pediatr 1978; 93: 6266.
  • 18
  • 19
    Deurenberger P, Van Der Kooij K, Evers P, Hulshof T. Assessment of body composition by bioelectrical impedance in a population aged greater than 60 years. Am J Clin Nutr 1990; 51: 36.
  • 20
    Akaike H. A new look at the statistical model identification. >IEEE Trans Automat Contr 1974; AC-19: 716722.
  • 21
    Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacl Ther 1995; 58: 512522.
  • 22
    Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10: 11711175.
  • 23
    Fleming RA, Milano GA, Gaspard MH, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993; 29A: 740744.
  • 24
    Naguib FNM, Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 54025412.
  • 25
    Etienne MC, Lagrange JL, Dassonville O, et al. A population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 22482253.
  • 26
    Nowakowska-Dulawa E. Circadian rhythm of 5-fluorouracil (FU) pharmacokinetics and tolerance. Chronobiologia 1990; 17: 2735.
  • 27
    Bocci G, Danesi R, Di Paolo A, et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 2000; 6: 30323037.
  • 28
    Gibaldi M, Koup JR. Pharmacokinetic concepts – Drug binding, apparent Volume of distribution and clearance. Eur J Clin Pharmacol 1981; 20: 299305.
  • 29
    Ikenaka K, Shirazaka T, Kitano S, Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979; 70: 353359.
  • 30
    Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38: 37843792.